Patents by Inventor Takahisa Hanada
Takahisa Hanada has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230390425Abstract: A conjugate of an anti-HER2 antibody site-specifically modified with a peptide and a chelating agent. The chelating agent is chelated with a metal radionuclide, the peptide and the chelating agent are linked by a linker (L), and the linker (L) does not contain a thiourea bond. A radiopharmaceutical including the conjugate as an active ingredient.Type: ApplicationFiled: October 15, 2021Publication date: December 7, 2023Applicant: NIHON MEDI-PHYSICS CO., LTD.Inventors: Minoru KAWATANI, Takahisa HANADA, Gota TONOYA, Takuya TAKEDA
-
Publication number: 20230288585Abstract: A radionuclide analysis apparatus includes: a radiation data detection unit that detects energy of alpha-ray emitted from a radionuclide in a sample and another energy emitted from another radionuclide different from the energy of the alpha-ray; a nuclide identification unit that identifies the radionuclide that has emitted the radiation by comparing a measurement spectrum Sa that is an energy spectrum based on the energy of the alpha-ray or another energy detected by the radiation data detection unit with a standard spectrum Ssa; and a distribution acquisition unit that obtains a distribution of a specific nuclide identified by the nuclide identification unit in the sample.Type: ApplicationFiled: August 11, 2021Publication date: September 14, 2023Applicant: Nihon Medi-Physics Co., Ltd.Inventor: Takahisa HANADA
-
Patent number: 9018260Abstract: Novel indansulfamide derivatives or a pharmaceutically acceptable salt thereof such as N-[(1S)-2,2,5,7-tetrafluoro-2,3-dihydro-1H-inden-1-yl]sulfamide, N-[(1S)-2,2,4,7-tetrafluoro-2,3-dihydro-1H-inden-1-yl]sulfamide, (+)-N-(2,2,4,6,7-pentafluoro-2,3-dihydro-1H-inden-1-yl)sulfamide, have an action of improving Seizure Severity Index (Score) in mice kindling model. Thus the compounds or the salt thereof are expected as a drug for treating epilepsy.Type: GrantFiled: June 17, 2013Date of Patent: April 28, 2015Assignee: Eisai R&D Management Co., Ltd.Inventors: Yuji Kazuta, Toru Watanabe, Keiichi Sorimachi, Minako Saito, Yoichi Kita, Toshiaki Tanaka, Hiroyuki Higashiyama, Takahisa Hanada, Tetsuyuki Teramoto, Takashi Kosasa, Yukio Ishikawa
-
Publication number: 20140371319Abstract: Novel indansulfamide derivatives or a pharmaceutically acceptable salt thereof such as N-[(1S)-2,2,5,7-tetrafluoro-2,3-dihydro-1H-inden-1-yl]sulfamide, N-[(1S)-2,2,4,7-tetrafluoro-2,3-dihydro-1H-inden-1-yl]sulfamide, (+)-N-(2,2,4,6,7-pentafluoro-2,3-dihydro-1H-inden-1-yl)sulfamide, have an action of improving Seizure Severity Index (Score) in mice kindling model. Thus the compounds or the salt thereof are expected as a drug for treating epilepsy.Type: ApplicationFiled: June 17, 2013Publication date: December 18, 2014Applicant: Eisai R&D Management Co., Ltd.Inventors: Yuji Kazuta, Toru Watanabe, Keiichi Sorimachi, Minako Saito, Yoichi Kita, Toshiaki Tanaka, Hiroyuki Higashiyama, Takahisa Hanada, Tetsuyuki Teramoto, Takashi Kosasa, Yukio Ishikawa
-
Publication number: 20100297181Abstract: The invention provides methods for treating epilepsy, mental disorders and/or deficits in sensory organ by administering to patients therapeutically effective amounts of AMPA receptor antagonists in combination with one or more other active ingredients useful for treating epilepsy, mental disorders and/or deficits in sensory organ. The invention also provides pharmaceutical combinations, kits, and pharmaceutical compositions comprising therapeutically effective amounts of AMPA receptor antagonists, and optionally, one or more other active ingredients that are useful for treating epilepsy, mental disorders and/or deficits in sensory organ.Type: ApplicationFiled: December 26, 2008Publication date: November 25, 2010Applicant: Eisai R&D Management Co., Ltd.Inventors: Takahisa Hanada, Shigeki Hibi, Kazuki Miyazaki
-
Publication number: 20100256191Abstract: The invention provides methods for treating epilepsy by administering to patients therapeutically effective amounts of AMPA receptor antagonists in combination with zonisamide useful for treating epilepsy. The invention also provides pharmaceutical combinations, kits, and pharmaceutical compositions comprising therapeutically effective amounts of AMPA receptor antagonists, and optionally, zonisamide that are useful for treating epilepsy.Type: ApplicationFiled: December 26, 2008Publication date: October 7, 2010Applicant: Eisai R&D Management Co., Ltd.Inventors: Takahisa Hanada, Shigeki Hibi, Kazuki Miyazaki
-
Publication number: 20100222354Abstract: The invention provides methods for treating and/or preventing neuropathic pain by administering to patients therapeutically effective amounts of AMPA receptor antagonists and aldose reductase inhibitors. The neuropathic pain may be diabetic neuropathy. The invention also provides kits, and pharmaceutical compositions comprising therapeutically effective amounts of AMPA receptor antagonists and aldose reductase inhibitors. The AMPA receptor antagonists may be, for example, 3-(2-cyanophenyl)-5-(2-pyridyl)-1-phenyl-1,2-dihydropyridin-2-one. The aldose reductase inhibitor may be, for example, ranirestat.Type: ApplicationFiled: July 11, 2008Publication date: September 2, 2010Applicant: Eisai R & D Management Co., Ltd.Inventors: Masanori Tsuno, Takahisa Hanada
-
Publication number: 20100179193Abstract: The invention provides methods for treating and/or preventing neuropathic pain by administering to patients therapeutically effective amounts of AMPA receptor antagonists and zonisamide. The neuropathic pain may be diabetic neuropathy. The invention also provides kits, and pharmaceutical compositions comprising therapeutically effective amounts of AMPA receptor antagonists and zonisamide. The AMPA receptor antagonist may be, for example, 3-(2-cyanophenyl)-5-(2-pyridyl)-1-phenyl-1,2-di-hydropyridin-2-one.Type: ApplicationFiled: July 11, 2008Publication date: July 15, 2010Applicant: Eisai R&D Management Co., LtdInventor: Takahisa Hanada
-
Publication number: 20100168174Abstract: The invention provides methods for treating and/or preventing neuropathic pain by administering to patients in need thereof therapeutically effective amounts of AMPA receptor antagonists; and cholinesterase inhibitors and/or anti-neuropathic pain agents. The neuropathic pain may be painful diabetic neuropathy. The invention also provides kits, and pharmaceutical compositions comprising therapeutically effective amounts of AMPA receptor antagonists; and cholinesterase inhibitors and/or anti-neuropathic pain agents. The AMPA receptor antagonists may be, for example, 3-(2-cyanophenyl)-5-(2-pyridyl)-1-phenyl-1,2-dihydropyridin-2-one. The cholinesterase inhibitor may be, for example, 1-benzyl-4-((5,6-dimethoxy-1-indanon)-2-yl)methylpiperidine (donepezil).Type: ApplicationFiled: July 11, 2008Publication date: July 1, 2010Applicant: Eisai R&D Management Co., Ltd.Inventor: Takahisa Hanada
-
Publication number: 20100099714Abstract: The invention provides methods for treating, preventing, and delaying the onset of neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, multiple sclerosis, Pick's disease, and the like), dementia, mild cognitive impairments, glaucoma, ocular hypertension, and pain (e.g., neuropathic pain, headaches, and the like) by administering therapeutically effective amounts of AMPA receptor antagonists and NMDA receptor antagonists to patents in need thereof. The invention also provides combinations, kits, and pharmaceutical compositions comprising therapeutically effective amounts of AMPA receptor antagonists and NMDA receptor antagonists. Exemplary AMPA receptor antagonists include 1,2-dihydropyridine compounds, such as 3-(2-cyanophenyl)-5-(2-pyridyl)-1-phenyl-1,2-dihydropyridin-2-one. Exemplary NMDA receptor antagonists include adamantane compounds, such as memantine.Type: ApplicationFiled: March 5, 2008Publication date: April 22, 2010Applicant: Eisai R&D Management Co., Ltd.Inventors: Hiroshi Yoshino, Takahisa Hanada, Shigeru Akasofu
-
Patent number: 7563811Abstract: The present invention provides a novel compound having an excellent AMPA receptor inhibitory action and/or kainate inhibitory action. A compound represented by the following formula, a salt thereof or hydrates thereof. In the formula, Q indicates NH, O or S; and R1, R2, R3, R4 and R5 are the same as or different from each other and each indicates hydrogen atom, a halogen atom, a C1-6 alkyl group or a group represented by the formula —X-A (wherein X indicates a single bond, an optionally substituted C1-6 alkylene group etc.; and A indicates an optionally substituted C6-14 aromatic hydrocarbocyclic group or 5- to 14-membered aromatic heterocyclic group etc.).Type: GrantFiled: July 6, 2005Date of Patent: July 21, 2009Assignee: Eisai R&D Management Co., Ltd.Inventors: Satoshi Nagato, Kohshi Ueno, Koki Kawano, Yoshihiko Norimine, Koichi Ito, Takahisa Hanada, Masataka Ueno, Hiroyuki Amino, Makoto Ogo, Shinji Hatakeyama, Yoshio Urawa, Hiroyuki Naka, Anthony John Groom, Leanne Rivers, Terence Smith
-
Publication number: 20090030017Abstract: The present invention relates to a therapeutic agent for dyskinesia excluding tremor, comprising 1,2-dihydropyridine compound, a salt thereof, or a solvate thereof, which shows AMPA receptor antagonism and is highly useful as a pharmaceutical drug.Type: ApplicationFiled: April 10, 2006Publication date: January 29, 2009Applicant: Eisai R & D Management Co., LtdInventors: Takahisa Hanada, Masataka Ueno, Sadako Kuno, Eiji Mizuta
-
Publication number: 20060189622Abstract: The present invention provides a novel compound exhibiting an excellent inhibitory action on AMPA receptor and/or kainate receptor. That is, it provides a compound represented by the following formula, a salt thereof or a hydrate of them. In the formula, A1, A2 and A3 are independent of each other and each represents a C3-8 cycloalkyl group, a C3-8 cycloalkenyl group, a 5- to 14-membered non-aromatic heterocyclic group, a C6-14 aromatic hydrocarbon cyclic group or a 5- to 14-membered aromatic heterocyclic group, each of which may be substituted; Q represents O, S or NH; Z represents C or N; X1, X2 and X3 are independent of each other and each represents a single bond, an optionally substituted C1-6 alkylene group, an optionally substituted C2-6 alkenylene group, an optionally substituted C2-6 alkynylene group, —NH—, —O—, —NHCO—, —CONH—, —SO0-2—, etc.Type: ApplicationFiled: April 21, 2006Publication date: August 24, 2006Inventors: Satoshi Nagato, Koki Kawano, Koichi Ito, Yoshihiko Norimine, Kohshi Ueno, Takahisa Hanada, Hiroyuki Amino, Makoto Ogo, Shinji Hatakeyama, Masataka Ueno, Anthony Groom, Leanne Rivers, Terence Smith
-
Publication number: 20050245581Abstract: The present invention provides a novel compound having an excellent AMPA receptor inhibitory action and/or kainate inhibitory action. A compound represented by the following formula, a salt thereof or hydrates thereof. In the formula, Q indicates NH, O or S; and R1, R2, R3, R4 and R5 are the same as or different from each other and each indicates hydrogen atom, a halogen atom, a C1-6 alkyl group or a group represented by the formula —X-A (wherein X indicates a single bond, an optionally sbutituted C1-6 alkylene group etc.; and A indicates an optionally substituted C6-14 aromatic hydrocarbocyclic group or 5- to 14-membered aromatic heterocyclic group etc.).Type: ApplicationFiled: July 6, 2005Publication date: November 3, 2005Inventors: Satoshi Nagato, Kohshi Ueno, Koki Kawano, Yoshihiko Norimine, Koichi Ito, Takahisa Hanada, Masataka Ueno, Hiroyuki Amino, Makoto Ogo, Shinji Hatakeyama, Yoshio Urawa, Hiroyuki Naka, Anthony Groom, Leanne Rivers, Terence Smith
-
Patent number: 6949571Abstract: The present invention provides a novel compound having an excellent AMPA receptor inhibitory action and/or kainate inhibitory action. A compound represented by the following formula, a salt thereof or hydrates thereof. In the formula, Q indicates NH, O or S; and R1, R2, R3, R4 and R5 are the same as or different from each other and each indicates hydrogen atom, a halogen atom, a C1-6 alkyl group or a group represented by the formula —X-A (wherein X indicates a single bond, an optionally substituted C1-6 alkylene group etc.; and A indicates an optionally substituted C6-14 aromatic hydrocarbocyclic group or 5- to 14-membered aromatic heterocyclic group etc.).Type: GrantFiled: June 8, 2001Date of Patent: September 27, 2005Assignee: Eisai Co., Ltd.Inventors: Satoshi Nagato, Kohshi Ueno, Koki Kawano, Yoshihiko Norimine, Koichi Ito, Takahisa Hanada, Masataka Ueno, Hiroyuki Amino, Makoto Ogo, Shinji Hatakeyama, Anthony John Groom, Leanne Rivers, Terence Smith
-
Publication number: 20040255344Abstract: It is intended to provide an animal model of urinary dysfunction induced by damage in brain nerve tissue in a small animal conveniently and at a high reproducibility. A rat in which the central urinary function alone is specifically damaged by regionally injuring the brain superior colliculus with the use of a legion generator. The animal model of urinary dysfunction is useful in a method of screening a therapeutic agent for urinary dysfunction.Type: ApplicationFiled: April 2, 2004Publication date: December 16, 2004Inventors: Miyuki Sakai, Atsuhiko Kubota, Takahisa Hanada
-
Patent number: 6825192Abstract: The present invention provides a hetrodiazinon compound having 2-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) receptor antagonistic action, which is represented by the following formula (I), a pharmacologically acceptable salt thereof or hydrates thereof. Wherein A represents O, S or a group represented by the formula NR3 (wherein R3 represents hydrogen atom or a lower alkyl group); R1 and R2 are the same as or different from each other and each represents an optionally substituted (hetero)aryl group etc.; and R4 and R5 are the same as or different from each other and each represents hydrogen atom, hydroxy, a halogen atom, nitrile group, nitro group, a lower alkyl group, a (hetero)aryl group etc.Type: GrantFiled: August 15, 2001Date of Patent: November 30, 2004Assignee: Eisai Co., Ltd.Inventors: Koichi Ito, Noritaka Kitazawa, Satoshi Nagato, Akiharu Kajiwara, Tatsuto Fukushima, Shinji Hatakeyama, Takahisa Hanada, Masataka Ueno, Kohshi Ueno, Koki Kawano
-
Publication number: 20040235866Abstract: A lymphocyte activation inhibitor and a therapeutic agent for an autoimmune disease, each comprising, as an active ingredient, a sulfonamide derivative or sulfonic acid ester derivative represented by the following general formula (I): 1Type: ApplicationFiled: March 4, 2004Publication date: November 25, 2004Inventors: Takahisa Hanada, Toshihiko Yamauchi, Kenichi Chiba, Takashi Owa, Takayuki Hida, Norimasa Miyamoto
-
Publication number: 20040023973Abstract: The present invention provides a novel compound having an excellent AMPA receptor inhibitory action and/or kainate inhibitory action. A compound represented by the following formula, a salt thereof or hydrates thereof.Type: ApplicationFiled: November 26, 2002Publication date: February 5, 2004Inventors: Satoshi Nagato, Kohshi Ueno, Koki Kawano, Yoshihiko Norimine, Koichi Ito, Takahisa Hanada, Masataka Ueno, Hiroyuki Amino, Makoto Ogo, Shinji Hatakeyama, Yoshio Urawa, Hiroyuki Naka, Anthony John Groom, Leanne Rivers
-
Publication number: 20030225081Abstract: The present invention provides a novel compound exhibiting an excellent inhibitory action on AMPA receptor and/or kainate receptor. That is, it provides a compound represented by the following formula, a salt thereof or a hydrate of them.Type: ApplicationFiled: March 18, 2003Publication date: December 4, 2003Inventors: Satoshi Nagato, Koki Kawano, Koichi Ito, Yoshihiko Norimine, Koshi Ueno, Takahisa Hanada, Hiroyuki Amino, Makoto Ogo, Shinji Hatakeyama, Masataka Ueno, Anthony John Groom, Leanne Rivers, Terence Smith